Olatunji B. Alese
Experienced in Glucagonoma

Dr. Olatunji B. Alese

Oncology
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Offers Telehealth
26 Years of Experience

Experienced in Glucagonoma
Emory health
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Olatunji Alese is an Oncologist in Atlanta, Georgia. Dr. Alese has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Glucagonoma. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Gastrointestinal Stromal Tumor, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 113 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Ibadan, 2000.0
Residency
New York Medical College (Metropolitan Hospital Center)
Specialties
Oncology
Licenses
Internal Medicine in GA
Board Certifications
American Board Of Internal Medicine, 2016
Fellowships
Emory University School of Medicine
Hospital Affiliations
Emory University Hospital Midtown
Emory University Hospital
Saint Joseph's Hospital Of Atlanta, Inc
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322
Call: 404-778-1900

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: January 23, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Hydroxychloroquine, Nab-paclitaxel, Paricalcitol
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: December 22, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
A Multicenter, Open-Label, Phase I Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects With Advanced or Metastatic Solid Tumors With IDH Mutations
Enrollment Status: Terminated
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: HMPL-306
Study Phase: Phase 1
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types
Enrollment Status: Active_not_recruiting
Publish Date: August 15, 2025
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug, Other
Study Drug: Romidepsin
Study Phase: Phase 1
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 11 Less Clinical Trials

109 Total Publications

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal: JCO precision oncology
Published: October 16, 2025
View All 109 Publications
Similar Doctors
Eyal Meiri
Experienced in Glucagonoma
Dr. Eyal Meiri
Oncology | Hematology
Experienced in Glucagonoma
Dr. Eyal Meiri
Oncology | Hematology

Piedmont Physicians Medical Oncology Atlanta

1800 Howell Mill Road Suite 300, 
Atlanta, GA 
 (7.0 miles away)
404-425-1777
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Eyal Meiri earned his medical degree from University of Toronto and completed his residency at Sinai Hospital of Detroit. He is fellowship-trained in oncology and hematology and is board certified in Internal Medicine and Medical Oncology. Prior to joining Piedmont, he was the Chief of Medical Oncology at Cancer Treatment Centers of America. Dr. Meiri has been practicing medicine for over 33 years and specializes in GI Cancers and Neuroendocrine Tumors.In his spare time, Dr. Meiri enjoys spending time reading, listening to audio books and podcasts, traveling, the Toronto Maple Leafs, and live concerts.Dr. Meiri is accepting new patients and welcomes most major insurance plans. Dr. Meiri is rated as a Distinguished provider by MediFind in the treatment of Glucagonoma. His top areas of expertise are Neuroendocrine Tumor, Pancreatic Cancer, Familial Pancreatic Cancer, and Colorectal Cancer.

Experienced in Glucagonoma
Dr. Jayanthi Srinivasiah
Oncology | Hematology
Experienced in Glucagonoma
Dr. Jayanthi Srinivasiah
Oncology | Hematology

Georgia Cancer Specialists

2712 Lawrenceville Highway, 
Decatur, GA 
 (2.8 miles away)
770-496-5555
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jayanthi Srinivasiah is a Hematologist and an Oncologist in Decatur, Georgia. Dr. Srinivasiah is rated as a Distinguished provider by MediFind in the treatment of Glucagonoma. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Bone Marrow Aspiration, and Gastrostomy. Dr. Srinivasiah is currently accepting new patients.

Eric D. Mininberg
Experienced in Glucagonoma
Dr. Eric D. Mininberg
Oncology | Hematology
Experienced in Glucagonoma
Dr. Eric D. Mininberg
Oncology | Hematology

Piedmont Cancer Institute, PC

290 Country Club Dr, Suite 100, 
Stockbridge, GA 
 (20.6 miles away)
678-854-9500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Mininberg is a Hematologist and an Oncologist in Stockbridge, Georgia. Dr. Mininberg is rated as a Distinguished provider by MediFind in the treatment of Glucagonoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Familial Colorectal Cancer, and Pleuropulmonary Blastoma. Dr. Mininberg is currently accepting new patients.

VIEW MORE GLUCAGONOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Alese's expertise for a condition
ConditionClose
  • Elite
  • Colorectal Cancer
    Dr. Alese is
    Elite
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Pancreatic Cancer
    Dr. Alese is
    Elite
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Distinguished
  • Appendix Cancer
    Dr. Alese is
    Distinguished
    . Learn about Appendix Cancer.
    See more Appendix Cancer experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Alese is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Familial Colorectal Cancer
    Dr. Alese is
    Distinguished
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Alese is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Gastrointestinal Stromal Tumor
    Dr. Alese is
    Distinguished
    . Learn about Gastrointestinal Stromal Tumor.
    See more Gastrointestinal Stromal Tumor experts
  • Lynch Syndrome
    Dr. Alese is
    Distinguished
    . Learn about Lynch Syndrome.
    See more Lynch Syndrome experts
View All 8 Distinguished Conditions
  • Advanced
  • Ampullary Cancer
    Dr. Alese is
    Advanced
    . Learn about Ampullary Cancer.
    See more Ampullary Cancer experts
  • Anal Cancer
    Dr. Alese is
    Advanced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Carcinoid Syndrome
    Dr. Alese is
    Advanced
    . Learn about Carcinoid Syndrome.
    See more Carcinoid Syndrome experts
  • Familial Prostate Cancer
    Dr. Alese is
    Advanced
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Fibrolamellar Carcinoma
    Dr. Alese is
    Advanced
    . Learn about Fibrolamellar Carcinoma.
    See more Fibrolamellar Carcinoma experts
  • Gallbladder Adenocarcinoma
    Dr. Alese is
    Advanced
    . Learn about Gallbladder Adenocarcinoma.
    See more Gallbladder Adenocarcinoma experts
View All 16 Advanced Conditions
  • Experienced
  • Adenoid Cystic Carcinoma
    Dr. Alese is
    Experienced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Alese is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Alese is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Alese is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Alveolar Soft Part Sarcoma
    Dr. Alese is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
  • Anemia
    Dr. Alese is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
View All 62 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment